Monoclonal Antibodies for Type VIII Collagen Epitope Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to quantify type VIII collagen levels in serum samples from patients with vascular remodeling and angiogenesis-related diseases such as fibrosis and cancer, which are crucial for diagnosis and prognosis.
Innovation Solution
Development of monoclonal antibodies and ELISA kits targeting the C-terminal and N-terminal epitopes of the mature α1 chain of collagen Type VIII, allowing for specific binding and quantification of these epitopes in serum samples, enabling the detection of elevated levels in diseases like idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect collagen types, then existing assays can measure common collagens (types I, III, IV), but type VIII collagen levels cannot be quantified in serum samples
Solution Approach 1:
The patent divides the collagen molecule into specific epitopic regions (N-terminal and C-terminal sequences) and develops antibodies targeting these discrete segments. This segmentation allows specific detection of type VIII collagen through epitope-based assays, resolving the difficulty of quantifying this collagen type in serum samples.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary molecules that specifically bind to type VIII collagen epitopes in serum samples. These antibodies serve as mediators between the collagen target and the detection system, enabling indirect but specific quantification of type VIII collagen levels through ELISA assays.
2Reliability
If antibodies are developed against collagen epitopes, then specific binding and quantification become possible, but the complexity of assay development increases
Solution Approach 1:
The patent focuses on developing antibodies against specific local regions (epitopes) of the collagen molecule rather than against the entire molecule. By targeting discrete N-terminal and C-terminal sequences, the assay achieves high specificity while maintaining manageable complexity through localized binding sites.
Solution Approach 2:
The patent utilizes the physical and chemical parameters of antibody-antigen binding (affinity, specificity, stoichiometry) to optimize the assay. By carefully selecting and characterizing antibodies with appropriate binding parameters, the system achieves reliable detection while controlling assay complexity through standardized immunological interactions.
3Adaptability or versatility
If type VIII collagen is used as a biomarker, then disease diagnosis and prognosis become possible, but validation and clinical application require extensive work
Solution Approach 1:
The patent performs preliminary characterization of type VIII collagen epitopes and develops validated antibodies before clinical application. By pre-characterizing the epitopes and optimizing antibody binding properties in advance, the validation process is streamlined, reducing the time required for clinical implementation while maintaining broad applicability across disease states.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies and ELISA kits demonstrate high specificity and sensitivity, showing elevated levels of C8-C and C8-N in serum from patients with COPD, IPF, and multiple cancer types, providing a robust biomarker for disease diagnosis and prognosis.
Implementation Method 1
an antibody which binds to an epitope present at the C-terminus of the collagen type VIII α1 chain
Implementation Method 2
an antibody which binds to an epitope present at the N-terminus of the mature collagen type VIII α1 chain
Data Source
AI summary
The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the α1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the α1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature α1 chain of collagen type VIII.